Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. ERTUGLIFLOZIN VERSUS DAPAGLIFLOZIN FOR PREVENTION OF HEART FAILURE EVENTS IN PATIENTS WITH REDUCED EJECTION FRACTION: NUMBER NEEDED TO TREAT AND ITS ASSOCIATED COSTS
  1. Home
  2. Publications
  3. ERTUGLIFLOZIN VERSUS DAPAGLIFLOZIN FOR PREVENTION OF HEART FAILURE EVENTS IN PATIENTS WITH REDUCED EJECTION FRACTION: NUMBER NEEDED TO TREAT AND ITS ASSOCIATED COSTS

ERTUGLIFLOZIN VERSUS DAPAGLIFLOZIN FOR PREVENTION OF HEART FAILURE EVENTS IN PATIENTS WITH REDUCED EJECTION FRACTION: NUMBER NEEDED TO TREAT AND ITS ASSOCIATED COSTS

Authors:
  • RARonen Arbel
    Ronen Arbel
  • EAEnis Aboalhasan
    Enis Aboalhasan
  • AHAriel Hammerman
    Ariel Hammerman
  • JAJoseph Azuri
    Joseph Azuri

Publisher website
Google Scholar
  • 1 May 2021
    • journal article
    • Published by Elsevier in JACC
    • Vol. 77  (18) , 776
    • DOI:10.1016/s0735-1097(21)02135-5
Abstract
No abstract available
Keywords
  • DAPAGLIFLOZIN
  • FRACTION (CHEMISTRY)
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.